Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.

Publication date: Dec 31, 2024

Concepts Keywords
Immunocompromised 2019-nCoV Vaccine mRNA-1273
Mrna 2019-nCoV Vaccine mRNA-1273
Spring Adult
Aged
BNT162 Vaccine
BNT162 Vaccine
Cost of Illness
Cost-Benefit Analysis
COVID-19
COVID-19 hospitalization
COVID-19 vaccine
COVID-19 Vaccines
COVID-19 Vaccines
decision analysis
economic modeling
Female
France
France
Hospitalization
Humans
Immunocompromised Host
Incidence
Male
Middle Aged
Quality-Adjusted Life Years
SARS-CoV-2
vaccine effectiveness
Vaccine Efficacy

Semantics

Type Source Name
disease MESH immunocompromised patients
disease MESH SARS-CoV-2 infections
disease MESH long COVID
disease IDO quality
disease MESH infection
disease MESH Uncertainty
disease IDO infection incidence

Original Article

(Visited 2 times, 1 visits today)